BrainChip Podcast Episode 4 A Conversation with Anil Mankar On this month’s podcast, Anil Mankar, BrainChip’s Co-Founder and Chief Development Officer, joined Louis DiNardo to discuss Beneficial AI, revolutionizing AI at the Edge, incremental learning and more. Mankar is an experienced semiconductor industry executive with great insight in driving business strategy for product development of system-level semiconductor products. “As the second founder of the company, Anil is the ‘Chip’ in BrainChip and has tremendous insight into the semiconductor industry in general and the success of BrainChip and Akida specifically,” said DiNardo. “As we generate more content for the BrainChip podcast through these monthly conversations, we are able to paint a more complete picture of how we fit into this leading-edge industry and how our approach to providing a high-performance, small, ultra-low power solution goes beyond what anyone else is currently capable of providing in neuromorphic computing. This latest entry into our podcast series is another not-to-be-missed event.” You can listen to the podcast HERE.

-->

In Case You Missed It: BrainChip Inc. and NaNose Medical Successfully Detect COVID-19 in Exhaled Breath with Fast High-Accuracy Results BrainChip announced progress in testing with the NaNose (Nano Artificial Nose) where patients’ exhaled breath samples were tested for COVID-19. NaNose Medical technology, based on the artificial nose developed at the Technion Israel Institute of Technology, has the same sensitivity to minute quantities of Volatile Organic Compounds (VOCs) as a dog’s nose. It has been tested by the Technion since 2017 to identify diseases including Parkinson’s, cancers, kidney failure, multiple sclerosis and infectious diseases such as COVID-19. NaNose Medical collected samples from 130 patients and sent nanomaterial sensor data to BrainChip’s Research Institute in Perth, Western Australia, which configured and trained its Akida™ neuromorphic processor to interpret the data using AI/ML. The system detected the instances of COVID-19 between a disease group and a healthy control group and Akida learned to recognize patterns of VOC biomarkers associated with an infection within seconds with a high level of accuracy in a minimal time frame. NaNose Medical is currently collecting samples from three primary worldwide locations and will work with BrainChip to evaluate the data. A study in China confirmed that breath sensor data is more accurate than the reverse transcription polymerase chain reaction (RT-PCR) test typically used. Accurate testing is key at early stages, even before symptoms manifest, and after treatment before patients are discharged into their communities. Using the NaNose Medical sensor array to collect the data, and Akida to perform the diagnosis, can have a higher rate of reliability than current testing methods and poses less risk to medical professionals because no saliva or mucus samples are collected. COVID-19 is known to be spread through respiratory droplets, and more recently has been confirmed to be airborne. READ THE REST OF THE ANNOUNCEMENT HERE